Technical Analysis for XCUR - Exicure, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
F | 0.33 | -26.34% | -0.12 |
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
MACD Bearish Signal Line Cross | Bearish | 0.00% | |
New 52 Week Closing Low | Bearish | 0.00% | |
Expansion Breakdown | Bearish Swing Setup | 0.00% | |
Volume Surge | Other | 0.00% | |
Wide Range Bar | Range Expansion | 0.00% | |
Lower Bollinger Band Walk | Weakness | 0.00% | |
New 52 Week Low | Weakness | 0.00% | |
Stochastic Reached Oversold | Weakness | 0.00% | |
BB Squeeze Ended | Range Expansion | 0.00% | |
Wide Bands | Range Expansion | 0.00% |
Alert | Time |
---|---|
10x Volume Pace | 4 days ago |
New 52 Week Low | 4 days ago |
Down 10% | 4 days ago |
Down 2 ATRs | 4 days ago |
Down 1 ATR | 4 days ago |
Free Daily (Stock) Chart Reading
- Earnings date: 05/13/2024
Exicure, Inc. Description
Exicure, Inc., a clinical-stage biotechnology company, develops gene regulatory and immuno-oncology therapeutics based on spherical nucleic acid (SNA) technology. Its three clinical programs include AST-008, which is in a Phase I clinical trial, an SNA consisting of toll-like receptor 9 that is designed for immuno-oncology applications; XCUR17, which is in a Phase I clinical trial, an SNA that targets the messenger RNA (mRNA) encoding interleukin 17 receptor alpha, a protein that helps in the initiation and maintenance of psoriasis; and AST-005, which is in a Phase I clinical trial, an SNA that targets TNF for the treatment of mild to moderate psoriasis. The company has collaboration agreement with Purdue Pharma L.P. Purdue Pharma for the development of AST-005; and license and development agreement DERMELIX, LLC, d/b/a Dermelix Biotherapeutics to research, develop, and commercialize Exicure's technology for the treatment of Netherton Syndrome and for five additional rare skin indications. Exicure, Inc. was founded in 2011 and is headquartered in Skokie, Illinois.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Life Sciences Acid Psoriasis Netherton Syndrome Oncology Applications Messenger RNA
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 1.5 |
52 Week Low | 0.31 |
Average Volume | 30,137 |
200-Day Moving Average | 0.63 |
50-Day Moving Average | 0.55 |
20-Day Moving Average | 0.48 |
10-Day Moving Average | 0.47 |
Average True Range | 0.04 |
RSI (14) | 20.00 |
ADX | 18.6 |
+DI | 11.20 |
-DI | 43.31 |
Chandelier Exit (Long, 3 ATRs) | 0.42 |
Chandelier Exit (Short, 3 ATRs) | 0.43 |
Upper Bollinger Bands | 0.56 |
Lower Bollinger Band | 0.40 |
Percent B (%b) | -0.45 |
BandWidth | 33.18 |
MACD Line | -0.03 |
MACD Signal Line | -0.03 |
MACD Histogram | -0.0079 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 0.50 | ||||
Resistance 3 (R3) | 0.51 | 0.46 | 0.47 | ||
Resistance 2 (R2) | 0.46 | 0.42 | 0.46 | 0.46 | |
Resistance 1 (R1) | 0.40 | 0.40 | 0.38 | 0.39 | 0.45 |
Pivot Point | 0.35 | 0.35 | 0.34 | 0.35 | 0.35 |
Support 1 (S1) | 0.29 | 0.31 | 0.27 | 0.28 | 0.21 |
Support 2 (S2) | 0.24 | 0.29 | 0.24 | 0.20 | |
Support 3 (S3) | 0.18 | 0.24 | 0.19 | ||
Support 4 (S4) | 0.17 |